Search Results
, alcohol, tobacco, and cannabis) were linked to higher scores of dimensions linked to mental health impairment, and lower scores of dimensions linked to well-being and resilience. Within this last group of non-psychedelic drugs, MDMA showed different
hallucinogens: eight participants. – Psilocybin: (“magic mushrooms”) ranging from one trial to monthly use, and from 1-year use up to 10 years; – LSD: ranging from one trial to monthly use, and from 1-year use up to 10 years; – MDMA (Ecstasy): ranging from one
mystical experiences and fewer challenging experiences after actual use. In a more recent report of MDMA users, Elmer, Vannoy, Studerus, and Lyubomirsky (2024) found significant differences by types of intentions for the majority of positive social
, A. , Jerome , L. , Mithoefer , A. , Wagner , M. , Walsh , Z. , Hamilton , S. , Yazar-Klosinski , B. , Emerson , A. & Doblin , R. ( 2019 ). MDMA-Assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3
is a member of a closed ayahuasca Facebook group, approximately between 22 and 67 years old and holds a rather high education degree and might be preexperienced in psychedelics such as psilocybin (“magic mushrooms”), MDMA (“ecstasy”), cannabis, and
) reported on the efficacy of MDMA and psilocybin in treating symptoms of PTSD and depression, but noted that confounders, patient bias, and challenges associated with blinding remain. Recent articles provide a valuable analysis of methodological problems
“relive the drug taking experience in their imagination” ( Baumann, 1970 , p. 20) with similar findings indicated more recently in a group of 3,4-Methylenedioxymethamphetamine (MDMA) users ( Hastings, 2006 ) suggesting the re-accessing of psychedelic
, E. , & Marcela Ot’alora , G. ( 2013 ). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder . Priest , G. , Tanaka , K. , & Weber , Z. ( 1996 ). Paraconsistent logic . Roseman , L. , Nutt , D. J
-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review . Psychopharmacology , 239 , 1945 – 1976 . https://doi.org/10.1007/s00213-022-06083-y . 10.1007/s00213-022-06083-y
. S. , & Brewerton , T. D. ( 2016 ). Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA . The Lancet Psychiatry, 3 ( 5 ), 481 – 488 . doi: 10.1016/S2215-0366(15)00576-3 10.1016/S2215
